The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Robin J. Prestwich, Fiona Errington, Rosa M. Diaz, Hardev S. Pandha, Kevin J. Harrington, Alan A. Melcher, Richard G. Vile

Research output: Contribution to journalReview article

130 Scopus citations

Abstract

The three-way interaction between oncolytic viruses, the tumor microenvironment, and the immune system is critical to the outcome of antitumor therapy. Classically, the immune system is thought to limit the efficacy of therapy, leading to viral clearance. However, preclinical and clinical data suggest that in some cases virotherapy may in fact act as cancer immunotherapy. In this review we discuss the ability of oncolytic viruses to alter the immunogenic milieu of the tumor microenvironment, and the role of innate and adaptive immunity in both restricting and augmenting therapy. Strategies to improve virotherapy by immunomodulation, including suppression or enhancement of the innate and adaptive responses, are discussed.

Original languageEnglish (US)
Pages (from-to)1119-1132
Number of pages14
JournalHuman gene therapy
Volume20
Issue number10
DOIs
StatePublished - Oct 2009

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.'. Together they form a unique fingerprint.

  • Cite this

    Prestwich, R. J., Errington, F., Diaz, R. M., Pandha, H. S., Harrington, K. J., Melcher, A. A., & Vile, R. G. (2009). The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Human gene therapy, 20(10), 1119-1132. https://doi.org/10.1089/hum.2009.135